FDA/CDC

Dexcom G6 gets FDA nod

Publish date: March 28, 2018

 


The Dexcom G6 integrated continuous glucose monitoring system just won FDA market clearance. Dexcom

Dexcom G6

“Along with this authorization, the FDA is establishing criteria, called special controls, which outline requirements for assuring iCGM devices’ accuracy, reliability and clinical relevance as well as describe the type of studies and data required to demonstrate acceptable iCGM performance. These special controls, when met along with general controls, provide reasonable assurance of safety and effectiveness for this device.”

The FDA evaluated data from two clinical studies of the Dexcom G6, which included 324 adults and children aged 2 years and older with diabetes. Both studies included multiple clinical visits within a 10-day period where system readings were compared to a laboratory test method that measures blood glucose values. No serious adverse events were reported during the studies.

Pages

Recommended Reading

FDA approves continuous glucose monitor with AI assistant
MDedge Internal Medicine
Three regular meals a day is best in T2DM
MDedge Internal Medicine
Red meat intake linked to NAFLD risk
MDedge Internal Medicine
SGLT2 inhibitors cut cardiovascular outcomes regardless of region
MDedge Internal Medicine
DPP-4 inhibitors increase IBD risk in diabetes
MDedge Internal Medicine
MDedge Daily News: Treating H. pylori slashed new gastric cancers
MDedge Internal Medicine
Major message: Most heart failure is preventable
MDedge Internal Medicine
Diabetes does its part to increase health care costs
MDedge Internal Medicine
Oral SGLT-2 inhibitor reduced liver fat in diabetics with NAFLD
MDedge Internal Medicine
VIDEO: Women living with HIV have more myocardial steatosis, reduced diastolic function
MDedge Internal Medicine